Expansion of Tumor-Infiltrating Lymphocytes from Melanoma Tumors
Autologous, in vitro-expanded tumor-infiltrating lymphocytes (TIL) have been successfully used for treatment of melanoma patients. Expansion of TIL from tumors is usually performed in two steps. The details of the procedure differ between different laboratories, but the general concept remains the same. In the first step, small fragments of a tumor are placed in culture medium containing one or more T cell stimulating growth factors. Here the most common protocol using interleukin (IL)-2 is described. The length of the first step is flexible to allow generation of enough cell to start the second step of the procedure. The second step is a so-called rapid expansion protocol (REP) where harvested TIL from the first step are induced to massive proliferation via triggering of their T cell receptor (TCR) complex in presence of an excess of feeder cells and, again, T cell stimulating growth factors. This second expansion step is usually around 2 weeks in length. Here will be described a REP that uses soluble anti-CD3 antibodies for TCR triggering, irradiated peripheral blood mononuclear cells (PBMC) as feeder cells, and IL-2 as the T cell growth factor. Furthermore, the described protocol utilizes gas-permeable cell culture flasks that yield large number of cells similar to conventional bioreactors but using standard laboratory equipment.
Key wordsImmunotherapy T cells Tumor-infiltrating lymphocytes In vitro expansion Adoptive cell transfer Interleukine-2 Anti-CD3 Feeder cells Gas-permeable cell culture flasks
- 4.Besser MJ, Shapira-Frommer R, Treves AJ et al (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16(9):2646–2655. https://doi.org/10.1158/1078-0432.CCR-10-0041CrossRefPubMedGoogle Scholar
- 9.Radvanyi LG, Bernatchez C, Zhang M et al (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758–6770. https://doi.org/10.1158/1078-0432.CCR-12-1177CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Forget MA, Haymaker C, Dennison JB et al (2016) The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity. Oncoimmunology 5(2):e1057386. https://doi.org/10.1080/2162402X.2015.1057386CrossRefPubMedGoogle Scholar
- 12.Forget MA, Malu S, Liu H et al (2014) Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J Immunother 37(9):448–460. https://doi.org/10.1097/CJI.0000000000000056CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Chacon JA, Wu RC, Sukhumalchandra P et al (2013) Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 8(4):e60031. https://doi.org/10.1371/journal.pone.0060031CrossRefPubMedPubMedCentralGoogle Scholar